You are here
November 21, 2023
PET scans of heart may aid early detection of Lewy body diseases
At a Glance
- NIH scientists found that PET scans of the heart may help to identify which at-risk people will later develop Parkinsonās disease or dementia with Lewy bodies.
- The findings may lead to improved approaches for early detection of these Lewy body diseases.
As the U.S. population grows older, thereās been a rise in age-related neurodegenerative diseases. Two such diseases are Parkinsonās disease and dementiaĀ with Lewy bodies. Because both involve abnormal structures, called Lewy bodies, inside nerve cells, they are referred to as Lewy body diseases. Lewy bodies contain a harmful form of a protein called alpha-synuclein. Symptoms of both diseases can include slow movement and cognitive impairment. Once symptoms arise, serious neurodegeneration has already occurred.
Researchers have been searching for ways to detect these Lewy body diseases earlier. Early diagnosis could help scientists study preventive approachesĀ like lifestyle changes, dietary supplements, or medications.
Five years ago, an NIH research team led by Dr. David S. Goldstein reported results from a study that followed 27 people for at least three years. All participants had three or more risk factors for Parkinsonās disease. Risk factors included a family history of the disease,Ā a reduced sense of smell,Ā dream enactment behavior (a sleep disorder in which people act out their dreams),Ā and orthostatic intolerance (problems upon standing, such as fainting or lightheadedness).
The researchers found evidence, using an imaging technique calledĀ 18F-dopamine PET scanning,Ā that people who later were diagnosed with Parkinsonās disease already had severe depletion of the chemical messenger norepinephrine in their hearts. Norepinephrine is derived from dopamine, which is lacking in particular brain centers in people with Parkinsonās disease.
In a continuation of that study, the team has now assessed 34 at-risk people over a longer time period.Ā Participants underwent 18F-dopamine PET scanning every 18 months for up to 7.5 years or until they were diagnosed with Parkinsonās disease. Results appeared in the Journal of Clinical Investigation on October 26, 2023.
The researchers confirmed that 18F-dopamine PET scans could distinguish the participants who would later be diagnosed with Parkinsonās or dementiaĀ with Lewy bodies. Those who had low levels of 18F-dopamine-derived radioactivity in the heart were highly likely to develop Parkinsonās or dementiaĀ with Lewy bodies. Of the nine people who had low radioactivity levels at their first scan, eight were later diagnosed with one of these Lewy body diseases. Of the 25 participants who initially had normal radioactivity levels, only one of the 11 who completed the sevenĀ years of follow-upĀ developed one of the diseases.
These findings support the view that disorders like Parkinsonās and dementiaĀ with Lewy bodies feature early involvement of the autonomic nervous system, the system that regulates automatic body processes like heart rate and blood pressure.
āWe think that in many cases of Parkinsonās and dementia with Lewy bodies, the disease processes donāt actually begin in the brain,ā Goldstein explains. Rather, autonomic processes may malfunction in other body organs first, before the disease process reachesĀ the brain. āThe loss of norepinephrine in the heart predicts and precedes the loss of dopamine in the brain in Lewy body diseases,ā he concludes.Ā
Such indicators outside the brain may help researchers detect the earliest signs of Lewy body diseasesĀ before symptoms appear.
Related Links
- A Potential Blood Test for Parkinsonās Disease
- Night Breathing Patterns Identify People with Parkinsonās Disease
- Test Distinguishes Parkinsonās Disease from Related Condition
- Tracking the Spread of Parkinsonās Proteins from Gut to Brain
- Appendix Linked to Toxic Parkinsonās Protein
- Risk Factors for Heart Disease Linked to Dementia
References: Goldstein DS, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S, Isonaka R, Wu T, Sharabi Y. J Clin Invest. 2023 Oct 26:e172460. doi: 10.1172/JCI172460. Online ahead of print. PMID:Ā 37883190.
Funding: NIHās National Institute of Neurological Disorders and Stroke (NINDS) and National Human Genome Research Institute (NHGRI).